However, on DSS treatment CD2–Tff2 mice showed insignificant expansion of CD11b+Gr-1+ IMCs, while Tff2-null mice had an exaggerated splenic IMC response with splenomegaly compare with wild-type and CD2–Tff2 mice (Fig. 2a,b and Supplementary Fig. 1a). The gene discussed is CD2; the disease is Splenomegaly.